---
title: Cancer collaborative initiatives
videoId: GLjKn61fJBw
---

From: [[oecdobservatoryofpublicsec3116]] <br/> 

This article summarizes a discussion among experts, including Angela Hansen from the Observatory of Public Sector Innovation at the OECD <a class="yt-timestamp" data-t="00:00:12">[00:00:12]</a>, Anders Brin from Vinnova <a class="yt-timestamp" data-t="00:02:37">[00:02:37]</a>, Suzanne Harkinson from AstraZeneca <a class="yt-timestamp" data-t="00:02:42">[00:02:42]</a>, Henry Lee from the Institute for Innovation and Public Purpose at University College London <a class="yt-timestamp" data-t="00:02:48">[00:02:48]</a>, Dr. Terry Terria Pizzo from the North Estonia Medical Center <a class="yt-timestamp" data-t="00:03:02">[00:03:02]</a>, Dr. Richard Rosenquist Brandell from the Karolinska Institute and chair of Genomic Medicine in Sweden <a class="yt-timestamp" data-t="00:03:07">[00:03:07]</a>, Dr. Ulrich Ringberg from the Karolinska Institute <a class="yt-timestamp" data-t="00:03:23">[00:03:23]</a>, Dr. Bettina Real from the Horizon Europe Mission Board of Cancer Patient Network <a class="yt-timestamp" data-t="00:03:31">[00:03:31]</a>, Dr. Bernd Stovasser from Sanofi <a class="yt-timestamp" data-t="00:03:41">[00:03:41]</a>, and Dr. Hans Hand, National Cancer Coordinator and co-founder of Vision Zero Cancer <a class="yt-timestamp" data-t="00:03:47">[00:03:47]</a>. The focus was on the essential nature of collaborative approaches to address cancer.

## The Need for [[missionoriented_innovation_in_cancer_prevention_and_care | Mission-Oriented Innovation in Cancer Prevention and Care]]

Cancer has become the leading cause of death in Western Europe, a problem that is expected to increase due to aging societies, making it a critical challenge to tackle <a class="yt-timestamp" data-t="00:04:47">[00:04:47]</a>. The inherent complexity of the problem, involving numerous parties, necessitates a structured approach for stakeholders to work together efficiently towards a clear goal within a reasonable timeframe <a class="yt-timestamp" data-t="00:04:58">[00:04:58]</a>.

### Benefits of a Mission-Oriented Approach
*   **Directionality**: Provides a clear common direction, overcoming the limited scope of individual organizations or mandates <a class="yt-timestamp" data-t="00:05:21">[00:05:21]</a>.
*   **Overcoming Silos**: Essential for tackling complex long-term challenges by breaking down organizational barriers and fostering new ways of collaborating <a class="yt-timestamp" data-t="00:01:03">[00:01:03]</a>.
*   **Bottom-up Experimentation**: Allows for grassroots innovation alongside strategic thinking <a class="yt-timestamp" data-t="00:01:09">[00:01:09]</a>.
*   **Shared Understanding and Commitment**: Joins forces to create a collective agreement and dedication <a class="yt-timestamp" data-t="00:06:08">[00:06:08]</a>.
*   **Systemic Integration**: Provides a framework for integrating various systemic aspects of innovation, including technology, infrastructure, behavior, and policy <a class="yt-timestamp" data-t="00:06:17">[00:06:17]</a>.
*   **Addressing Fragmentation**: Aims to circumvent fragmentation in research, healthcare, and education, which has been a major problem for the last two decades <a class="yt-timestamp" data-t="00:10:21">[00:10:21]</a>.

A [[missionoriented_innovation_in_cancer_prevention_and_care | mission-oriented approach]] is particularly well-suited for health topics due to their multi-causality and uncertain cause-and-effect relationships <a class="yt-timestamp" data-t="00:08:05">[00:08:05]</a>. In health, this approach is often implicit, but making it explicit proves beneficial <a class="yt-timestamp" data-t="00:06:44">[00:06:44]</a>.

### Opportunities in [[precision_medicine_for_cancer | Precision Medicine for Cancer]]
The biggest opportunities for [[building_personalized_medicine_approaches_in_healthcare | personalized medicine]] in cancer lie in areas where multi-sectoral knowledge, experience, and decision-making power can be combined <a class="yt-timestamp" data-t="00:08:41">[00:08:41]</a>. This includes:
*   **Prevention and Early Detection**: Huge opportunities exist, for example, in lung cancer, to prevent more cases and detect them earlier among risk groups and never-smokers, saving many lives <a class="yt-timestamp" data-t="00:09:32">[00:09:32]</a>. Research in prevention, though historically underfunded, has the potential to reduce cancer by 40% <a class="yt-timestamp" data-t="00:11:35">[00:11:35]</a>.
*   **Improving Patient Outcomes**: Research should focus on improving outcomes for at-risk individuals and patients <a class="yt-timestamp" data-t="00:10:44">[00:10:44]</a>.
*   **Comprehensive Continuum of Care**: Covering prevention, therapy, and the complete continuum of care with all components is extremely important <a class="yt-timestamp" data-t="00:11:00">[00:11:00]</a>.
*   **Infrastructure**: Robust infrastructure, such as comprehensive cancer centers and their networks, is crucial to reach all patients and address inequalities <a class="yt-timestamp" data-t="00:11:12">[00:11:12]</a>.
*   **Deepening Biological Understanding**: Expanding knowledge in cancer biology and fostering collaboration to analyze histogenetic groups and subgroups is necessary due to the heterogeneity of cancer <a class="yt-timestamp" data-t="00:12:30">[00:12:30]</a>.
*   **Clinical Trials**: Structuring clinical trials for the next generation of more complex studies is a big task <a class="yt-timestamp" data-t="00:13:21">[00:13:21]</a>.

## Strategies for Effective [[international_collaboration_on_innovation | International Collaboration on Innovation]]

### Engaging Stakeholders
*   **Broad Mix of Expertise**: Involving a wide range of expertise at different levels, from policy development to grassroots implementation <a class="yt-timestamp" data-t="00:17:25">[00:17:25]</a>.
*   **Common Language**: Translating policy language into more inclusive language to involve a wider array of stakeholders <a class="yt-timestamp" data-t="00:01:24">[00:01:24]</a>.
*   **Patient Involvement**: Actively involving patients and their relatives in all steps of the process is crucial <a class="yt-timestamp" data-t="00:17:48">[00:17:48]</a>. Patients should be involved in clinical trials and the sharing of comprehensive cancer centers <a class="yt-timestamp" data-t="00:13:47">[00:13:47]</a>. While widely acknowledged, the "how" of involving patients effectively, ensuring representativeness and providing necessary resources, remains a challenge <a class="yt-timestamp" data-t="00:36:41">[00:36:41]</a>.
*   **Unusual Partners**: Collaborating with unexpected partners, such as ministries of transport or education, can help address broader societal gaps that impact healthcare access and prevention <a class="yt-timestamp" data-t="00:25:50">[00:25:50]</a>.
*   **Penta Helix Model**: Richard Rosenquist Brandell describes a "penta helix" model involving academia, healthcare, patients, authorities, and industry, emphasizing a shared desire to work together despite differing traditional work habits <a class="yt-timestamp" data-t="00:18:33">[00:18:33]</a>.

### Building Trust and [[publicprivate_partnerships_for_data_sharing | Public-Private Partnerships for Data Sharing]]
*   **Trust as a Key**: Trust is paramount and requires hard work, joint discussion, and shared vision development <a class="yt-timestamp" data-t="00:24:18">[00:24:18]</a>.
*   **Shared Commitment**: Stakeholders are committed and willing to take responsibility <a class="yt-timestamp" data-t="00:19:24">[00:19:24]</a>.
*   **Neutral Arenas**: Providing a neutral arena with neutral leadership can help overcome difficulties in [[publicprivate_partnerships_for_data_sharing | public-private partnerships]] or collaborations involving regulatory agencies <a class="yt-timestamp" data-t="00:29:29">[00:29:29]</a>.
*   **Formal Frameworks**: Clear legal and intellectual property (IP) frameworks are essential for large [[publicprivate_partnerships_for_data_sharing | public-private partnerships]] to ensure trust and avoid disputes <a class="yt-timestamp" data-t="00:23:47">[00:23:47]</a>.
*   **Professional Alliance Management**: Large projects require professional alliance management beyond what researchers alone can handle <a class="yt-timestamp" data-t="00:24:55">[00:24:55]</a>.
*   **Overcoming Silos in Industry**: Industry partners, often unaccustomed to collaborating amongst themselves, need to learn to share knowledge, recognizing that the payoff of collaboration outweighs the risks <a class="yt-timestamp" data-t="00:45:00">[00:45:00]</a>. This learning process builds long-term relationships <a class="yt-timestamp" data-t="00:46:38">[00:46:38]</a>.

### Data Management and Digital Transformation
*   **Data Importance**: Data is extremely important, encompassing quality, standards, access, data protection, and cybersecurity, which should serve as a support tool, not a limit <a class="yt-timestamp" data-t="00:33:13">[00:33:13]</a>.
*   **Patient-Reported Data**: Platforms for patient-reported experiences, outcomes, and incidents are valuable for online monitoring and information exchange <a class="yt-timestamp" data-t="00:33:41">[00:33:41]</a>.
*   **Integration of Information**: A key challenge is integrating genetic and other patient information into routine healthcare work, requiring awareness-raising and engagement of both medical professionals and patients <a class="yt-timestamp" data-t="00:34:49">[00:34:49]</a>.

### Funding and Regulatory Aspects
*   **Long-Term Funding**: Innovation funding is traditionally project-based and short-term; funders need to collaborate more closely to ensure a long-term perspective on funding sustainability <a class="yt-timestamp" data-t="00:30:33">[00:30:33]</a>.
*   **Health Economics**: More work is needed in health economics to fully understand the societal benefits of [[missionoriented_innovation_in_cancer_prevention_and_care | mission-oriented innovation]] and develop holistic, sustainable reimbursement models <a class="yt-timestamp" data-t="00:30:48">[00:30:48]</a>.
*   **Case-Based Approach**: The ability to work case-based and build demonstrators is crucial rather than attempting to change the entire system at once <a class="yt-timestamp" data-t="00:31:01">[00:31:01]</a>.
*   **Regulatory Adaptation**: Governance structures, including administrative routines and annual budget cycles within healthcare, need to be jointly addressed and adapted <a class="yt-timestamp" data-t="00:38:40">[00:38:40]</a>. New policies must consider the consequences of new knowledge; for example, if genetic testing reveals a high risk, there must be agreed-upon services and funding for follow-up care <a class="yt-timestamp" data-t="00:35:36">[00:35:36]</a>.

## Examples of Collaborative Initiatives

*   **Vision Zero Cancer**: An initiative in Sweden supported by Vinnova's "Vision-Driven Health" program, which adopts an agile approach to support [[missionoriented_innovation_in_cancer_prevention_and_care | mission-oriented innovation]] <a class="yt-timestamp" data-t="00:29:48">[00:29:48]</a>. It begins with specific areas like lung cancer to address systemic innovation in a scalable way <a class="yt-timestamp" data-t="00:31:11">[00:31:11]</a>.
*   **Genomic Medicine Sweden**: A large national initiative focused on the hands-on implementation of [[precision_medicine_for_cancer | precision medicine]] in healthcare <a class="yt-timestamp" data-t="00:18:07">[00:18:07]</a>. There are over 34 national/regional [[building_personalized_medicine_approaches_in_healthcare | precision medicine]] initiatives in Europe, highlighting the need for [[international_collaboration_on_innovation | international collaboration]] for rare diseases or cancers <a class="yt-timestamp" data-t="00:19:51">[00:19:51]</a>.
*   **Innovative Medicines Initiative (IMI)**: A major European endeavor, soon to be the Innovative Health Initiative, involving a 10 billion Euro budget, half from the European Commission and half from industry in in-kind contributions <a class="yt-timestamp" data-t="00:21:54">[00:21:54]</a>. It includes about 12 major cancer projects with a budget of almost 200 million Euros, bringing together over 200 partners from 19 countries (academia, industry, SMEs, philanthropy) to catalyze oncology research and development <a class="yt-timestamp" data-t="00:22:41">[00:22:41]</a>. This initiative demonstrates the feasibility of [[publicprivate_partnerships_for_data_sharing | public-private partnerships]] and addresses the challenge of industries collaborating with each other <a class="yt-timestamp" data-t="00:45:00">[00:45:00]</a>.

## Lessons Learned and Future Outlook

*   **COVID-19 as a Demonstrator**: The rapid development and large-scale deployment of new therapies during the COVID-19 pandemic serve as a powerful demonstrator that Europe is capable of significant collaborative achievements, challenging the notion that similar efforts are impossible in cancer <a class="yt-timestamp" data-t="00:48:11">[00:48:11]</a>. This experience has created a unique opportunity to redefine cancer care and move towards a "new normal" <a class="yt-timestamp" data-t="00:54:22">[00:54:22]</a>.
*   **Leadership and Management**: Success hinges on strong leadership and professional management of multiple stakeholders, rather than relying solely on individual experts <a class="yt-timestamp" data-t="00:49:57">[00:49:57]</a>.
*   **Communication and Transparency**: Clear communication and transparency among all parties are crucial to avoid repetition and effectively use resources <a class="yt-timestamp" data-t="00:43:09">[00:43:09]</a>. Lessons learned from cancer initiatives can be valuable for other healthcare areas, such as chronic diseases <a class="yt-timestamp" data-t="00:43:13">[00:43:13]</a>.
*   **Sustainable Infrastructure**: To achieve sustainable change, robust infrastructure, particularly integrated comprehensive cancer centers that combine research, education, and healthcare, is essential <a class="yt-timestamp" data-t="00:39:41">[00:39:41]</a>.

The overall sentiment is one of optimism, with stakeholders widely agreeing on the direction forward <a class="yt-timestamp" data-t="00:51:17">[00:51:17]</a>. There is a strong willingness in Europe to focus on health and cancer, making now the opportune time to drive these initiatives <a class="yt-timestamp" data-t="00:50:39">[00:50:39]</a>. By [[cocreation_and_international_collaboration | joining forces]] and fostering a learning process, the vision of [[precision_medicine_for_cancer | precision medicine]] in cancer can be realized <a class="yt-timestamp" data-t="00:52:13">[00:52:13]</a>.